Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Long-term Administration Study of MT-2412 in Patients With Type 2 Diabetes Mellitus

Trial Profile

Long-term Administration Study of MT-2412 in Patients With Type 2 Diabetes Mellitus

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 29 Sep 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Canagliflozin/teneligliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Mitsubishi Tanabe Pharma Corporation
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 13 Jun 2017 Results from phase 3 studies in Japanese patient with Type-2-diabetes-mellitus (MT-2412-J01, MT-2412-J02 and MT-2412-J03) presented at the 77th Annual Scientific Sessions of the American Diabetes Association
    • 05 Aug 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top